Karger Publishers
Browse
Supplementary material-CARE_checklist_completed.pdf (176.58 kB)

Supplementary Material for: New perspectives in the treatment of inflammatory myofibroblastic tumor with ALK translocation. Case Report.

Download (176.58 kB)
dataset
posted on 2024-07-03, 12:38 authored by BenedettiPedroza J., CarrascoGarcía I., MartínezBernal G., MirasRodriguez I.
Inflammatory myofibroblastic tumor is a rare entity, classified within soft tissue sarcomas. It is an intermediate malignancy tumor, which seldom presents as metastatic disease. The treatment of choice is surgery, except in cases where surgery is not possible due to localization or if it presents with metastatic disease. Approximately 50% of IMTs will exhibit ALK translocation, providing a therapeutic target for these patients. A case is presented of a patient with metastatic IMT in complete response to treatment with alectinib, maintained for over 4 years.

History

Usage metrics

    Case Reports in Oncology

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC